Plant-derived proteins;
Clinical development;
Commercialization;
Biosafety;
Regulation;
HIGH-LEVEL EXPRESSION;
HUMAN GROWTH-HORMONE;
B SURFACE-ANTIGEN;
HETEROLOGOUS PROTEIN-PRODUCTION;
RECOMBINANT HUMAN LACTOFERRIN;
HUMAN MONOCLONAL-ANTIBODY;
VIRUS-LIKE PARTICLES;
TRANSGENIC TOBACCO;
TRANSIENT EXPRESSION;
TRANSFORMED TOBACCO;
D O I:
10.1016/j.biotechadv.2010.11.004
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
Plant molecular farming (PMF) is a new branch of plant biotechnology, where plants are engineered to produce recombinant pharmaceutical and industrial proteins in large quantities. As an emerging subdivision of the biopharmaceutical industry. PMF is still trying to gain comparable social acceptance as the already established production systems that produce these high valued proteins in microbial, yeast, or mammalian expression systems. This article reviews the various cost-effective technologies and strategies, which are being developed to improve yield and quality of the plant-derived pharmaceuticals, thereby making plant-based production system suitable alternatives to the existing systems. It also attempts to overview the different novel plant-derived pharmaceuticals and non-pharmaceutical protein products that are at various stages of clinical development or commercialization. It then discusses the biosafety and regulatory issues, which are crucial (if strictly adhered to) to eliminating potential health and environmental risks, which in turn is necessary to earning favorable public perception, thus ensuring the success of the industry. (C) 2010 Elsevier Inc. All rights reserved.
机构:
Nanjing Forestry Univ, Coll Life Sci, Nanjing 210037, Peoples R China
Nanjing Agr Univ, Coll Life Sci, Nanjing 210095, Peoples R ChinaNanjing Forestry Univ, Coll Life Sci, Nanjing 210037, Peoples R China